COX inhibitors for the treatment of migraine

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 13, 2014, Pages 1863-1874

  Silberstein, Stephen D ^a   Stirpe, Jessica C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

COX inhibitor; Migraine; NSAID

Indexed keywords

PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL; DRUG COMBINATION; DRUG POTENTIATION; HUMAN; MIGRAINE DISORDERS;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MIGRAINE DISORDERS;

EID: 84905822430     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.937704     Document Type: Review

References (102)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalagia 2004;24:1-160
3. Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008;21:331-7
4. World Health Organization. The World Health Report 2001: Mental health, new understanding, new hope. Isr J Psychiatry Relat Sci 2002;39(1):50-6
5. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998;47(Suppl 2):S78-87
6. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:2S-8S. discussion 21S-22S
7. Loo CY, Tan HJ, Teh HS, Raymond AA. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 2007;48:834-9
8. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355-63
9. Diener HC. Headache: insight, understanding, treatment and patient management. Int J Clin Pract Suppl 2013;178:33-6
10. Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254:705-12
11. Da Silva AN, Tepper SJ. Acute treatment of migraines. CNS Drugs 2012;26:823-39
12. Rothrock JF. Non-steroidal anti-inflammatory drugs (NSAIDs) for acute migraine treatment. Headache 2010;50:1635-6
13. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
14. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60:935-40
15. Hauge AW, Kirchmann M, Olesen J. Characterization of consistent triggers of migraine with aura. Cephalalgia 2011;31:416-38
16. Zhang X, Levy D, Noseda R, et al. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 2010;30:8807-14
17. Messlinger K, Strassman AM, Burstein R. Anatomy and physiology of pain-sensitive cranial structures. In: Silberstein SD, Lipton RB, Dodick DW, editors. Wolffs headache and other head pain. 8th edition. Oxford University Press; New York: 2008. p. 95-104
18. Strassman AM, Weissner W, Williams W, et al. Axon diameters and intradural trajectories of the dural innervation in the rat. J Comp Neurol 2004;473:364-76
19. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat aura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992;48:187-203
20. Levy D. Migraine pain and nociceptor activation-where do we stand? Headache 2010;50:909-16
21. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;384:560-4
22. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24
23. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002;346:257-70
24. Whyte C, Tepper SJ, Evans RW. Expert opinion: rescue me: rescue medication for migraine. Headache 2010;50:307-13
25. Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia 1995;15(Suppl 15):14-20
26. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-17
27. Myren M, Baun M, Ploug KB, et al. Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine. Cephalalgia 2010;30:1110-22
28. Davis RJ, Murdoch CE, Ali M, et al. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 2004;141:580-5
29. Maubach KA, Davis RJ, Clark DE, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 2009;156:316-27
30. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999;89:901-7
31. Jenkins DW, Feniuk W, Humphrey PP. Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol 2001;134:1296-302
32. Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ. Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett 2004;366:241-4
33. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2 (PGE2) induces headache in healthy subjects. Cephalalgia 2009;29:509-19
34. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandins in migraine: update. Curr Opin Neurol 2013;26:269-75
35. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol 2013;75:365-91
36. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache 2012;52:467-82
37. Sokolov AY, Lyubashina OA, Panteleev SS, Chizh BA. Neurophysiological markers of central sensitisation in the trigeminal pathway and their modulation by the cyclo-oxygenase inhibitor ketorolac. Cephalalgia 2010;30:1241-9
38. Jakubowski M, Levy D, Kainz V, et al. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 2007;148:573-83
39. Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005;45:850-61
40. Schoenen J, De Klippel N, Giurgea S, et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia 2008;28:1095-105
41. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-10
42. Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005;45:850-61
43. Weatherall MW, Telzerow AJ, Cittadini E, et al. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology 2010;75:1098-103
44. Hautaniemi T, Petrenko N, Skorinkin A, Giniatullin R. The inhibitory action of the antimigraine nonsteroidal antiinflammatory drug naproxen on P2X3 receptor-mediated responses in rat trigeminal neurons. Neuroscience 2012;209:32-8
45. Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: inhibition by naproxen. Eur J Neurosci 2008;27:917-22
46. Rizzoli PB. Acute and preventive treatment of migraine. Continuum (Minneap Minn) 2012;18:764-82
47. Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010;50:808-18
48. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:Cd008041
49. Lipton RB, Goldstein J, Baggish JS, et al. Aspirin is efficacious for the treatment of acute migraine. Headache 2005;45:283-92
50. MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebocontrolled study. Headache 2002;42:249-55
51. Lampl C, Voelker M, Steiner TJ. Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity. Headache 2012;52:48-56
52. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004;52:50-6
53. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24:947-54
54. Leniger T, Pageler L, Stude P, et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005;45:42-6
55. Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;10:Cd009455
56. Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007;41:1782-91
57. Codispoti JR, Prior MJ, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 2001;41:665-79
58. Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:Cd008783
59. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia 1999;19:232-40
60. Peroutka SJ, Lyon JA, Swarbrick J, et al. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. Headache 2004;44:136-41
61. Vecsei L, Gallacchi G, Sagi I, et al. Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study. Cephalalgia 2007;27:29-34
62. Rothrock JF. PRO-513 for acute migraine treatment. Headache 2007;47(10):1459
63. Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 2006;26:537-47
64. Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 2010;30:1336-45
65. Rapoport AM. Acute treatment of migraine: established and emerging therapies. Headache 2012;52(Suppl 2):60-4
66. Rapoport AM. The therapeutic future in headache. Neurol Sci 2012;33(Suppl 1):S119-25
67. Tepper DE. Nasal sprays for the treatment of migraine. Headache 2013;53:577-8
68. Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003;21:173-5
69. Seim MB, March JA, Dunn KA. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998;5:573-6
70. Cady RJ, Shade CL, Cady RK. Advances in drug development for acute migraine. Drugs 2012;72:2187-205
71. Pfaffenrath V, Fenzl E, Bregman D, Farkkila M. Intranasal ketorolac tromethamine (SPRIX(R)) containing 6%of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia 2012;32:766-77
72. Ravishankar K, Tayade H, Mandlik R. Sublingual piroxicam in migraine without aura. J Assoc Physicians India 2011;59:494-7
73. Krymchantowski AV, Barbosa JS, Cheim C, Alves LA. Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebocontrolled study. Arq Neuropsiquiatr 2001;59:46-9
74. Krymchantowski AV, Peixoto P, Higashi R, et al. Lysine clonixinate vs naproxen sodium for the acute treatment of migraine: a double-blind, randomized, crossover study. MedGenMed 2005;7:69
75. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 2002;42:862-71
76. Tulunay FC, Ergun H, Gulmez SE, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebocontrolled, multi-center study. Funct Neurol 2004;19:197-202
77. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 2002;58:1660-5
78. Saper J, Dahlof C, So Y, et al. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache 2006;46:264-75
79. Silberstein S, Tepper S, Brandes J, et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004;62:1552-7
80. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J 2004;80:720-3
81. Krymchantowski AV. The use of combination therapies in the acute management of migraine. Neuropsychiatr Dis Treat 2006;2:293-7
82. Diener HC, Peil H, Aicher B. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebocontrolled parallel group study. Cephalalgia 2011;31:1466-76
83. Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005;25:776-87
84. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006;46:444-53
85. Hoy SM, Scott LJ. Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache. CNS Drugs 2011;25:343-58
86. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005;45:983-91
87. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000;58:428-30
88. Landy S, Hoagland R, Hoagland NA. Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention. Headache 2012;52:133-9
89. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004;4:10
90. Blumenfeld A, Gennings C, Cady R. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache 2012;52:636-47
91. Shiyani B, Gattani S, Surana S. Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 2008;9:818-27
92. Cantisani TA, Celani MG, Hankey GJ, Sandercock PA. An old drug for a common disease. J Neurol Neurosurg Psychiatry 2013;84:473-4
93. Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002;47:88-98
94. Bulloch B, Tenenbein M. Emergency department management of pediatric migraine. Pediatr Emerg Care 2000;16:196-201
95. Turkewitz LJ, Casaly JS, Dawson GA, et al. Self-administration of parenteral ketorolac tromethamine for head pain. Headache 1992;32:452-4
96. Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53
97. MacGregor EA. Prevention and treatment of menstrual migraine. Drugs 2010;70:1799-818
98. Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004;63:2215-24
99. O'Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother 2012;13:959-66
100. Lipton RB, Serrano D, Nicholson RA, et al. Impact of NSAID and triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2013;53(10):1548-63
101. Starling AJ, Hoffman-Snyder C, Halker RB, et al. Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Neurologist 2011;17:297-9
102. Di W, Shi X, Zhu Y, et al. Overuse of paracetamol caffeine aspirin powders affects cerebral glucose metabolism in chronic migraine patients. Eur J Neurol 2013;20:655-62